Clinical-stage immuno-oncology company Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has reported encouraging early response ...

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

Domain adaptation may be a novel creative solution to predict infection risk in patients with chronic lymphocytic leukemia ...

CAR T-cell therapy positively benefitted patients with patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Breyanzi (lisocabtagene maraleucel), ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of certain patients with relapsed ...

BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, ...

A BTK inhibitor combined with standard R-CHOP produced rapid, PET-defined complete remission in high-risk DLBCL-type Richter syndrome with TP53 deletion. Delaying ibrutinib until cycle 2 was used as a ...

In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.

The approval was based on the AMPLIFY trial, which evaluated acalabrutinib alongside venetoclax in adults with previously untreated CLL without del(17p) or TP53 mutation.

Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had ...

Leukemia and lymphoma are cancers that affect white blood cells, but they are separate conditions. In some people, they can occur simultaneously. It is possible, but very rare, to have both leukemia ...